Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders.
Endocannabinoids and their receptors, mainly the CB(1) receptor type, function as a retrograde signaling system in many synapses within the CNS, particularly in GABAergic and glutamatergic synapses. They also play a modulatory function on dopamine (DA) transmission, although CB(1) receptors do not appear to be located in dopaminergic terminals, at least in the major brain regions receiving dopaminergic innervation, e.g., the caudate-putamen and the nucleus accumbens/prefrontal cortex. Therefore, the effects of cannabinoids on DA transmission and DA-related behaviors are generally indirect and exerted through the modulation of GABA and glutamate inputs received by dopaminergic neurons. Recent evidence suggest, however, that certain eicosanoid-derived cannabinoids may directly activate TRPV(1) receptors, which have been found in some dopaminergic pathways, thus allowing a direct regulation of DA function. Through this direct mechanism or through indirect mechanisms involving GABA or glutamate neurons, cannabinoids may interact with DA transmission in the CNS and this has an important influence in various DA-related neurobiological processes (e.g., control of movement, motivation/reward) and, particularly, on different pathologies affecting these processes like basal ganglia disorders, schizophrenia, and drug addiction. The present review will address the current literature supporting these cannabinoid-DA interactions, with emphasis in aspects dealing with the neurochemical, physiological, and pharmacological/therapeutic bases of these interactions.
Fernández-Ruiz
Javier
J
Departamento de Bioquímica y Biología Molecular and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Universidad Complutense, Madrid, Spain. jjfr@med.ucm.es <jjfr@med.ucm.es>
Hernández
Mariluz
M
Ramos
José A
JA
D000818:Animals; D002186:Cannabinoids / Q000037:antagonists & inhibitors / Q000378:metabolism*; D002493:Central Nervous System Diseases / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D002540:Cerebral Cortex / Q000378:metabolism; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism*; D006801:Humans; D008032:Limbic System / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology
D002186:Cannabinoids; D004298:Dopamine
Eur J Neurosci. 2001 Dec;14(11):1827-32
11860478
Brain Res. 2002 Sep 6;948(1-2):155-8
12383968
Neurosci Lett. 2008 Jun 13;438(1):10-3
18457923
AAPS J. 2009 Mar;11(1):39-44
19184452
Neurobiol Learn Mem. 2009 Oct;92(3):391-9
19450698
Eur Neuropsychopharmacol. 2009 Mar;19(3):196-204
19116182
Behav Brain Res. 2001 Jan 8;118(1):61-5
11163634
J Pharmacol Exp Ther. 2007 Oct;323(1):318-26
17630359
Neurobiol Dis. 2009 Oct;36(1):70-80
19591935
Neuroscience. 2000;99(4):661-7
10974429
Br J Pharmacol. 2003 Feb;138(4):544-53
12598408
Braz J Med Biol Res. 2006 Apr;39(4):421-9
16612464
Eur J Pharmacol. 1999 Nov 3;383(3):R1-2
10594337
Neurochem Res. 2001 Sep;26(8-9):1015-21
11699929
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3655-60
10725386
Psychopharmacology (Berl). 2003 Jul;168(1-2):164-169
12669182
Neurobiol Learn Mem. 2004 Mar;81(2):144-9
14990234
Psychiatry Res. 2001 Oct 1;107(3):173-7
11566433
Brain Res. 2006 Feb 16;1073-1074:209-19
16412990
Brain Res Bull. 2003 Jul 15;61(2):125-8
12831997
Neurosci Lett. 2008 Jan 24;431(1):6-11
18069125
Mol Psychiatry. 2004 Oct;9(10):916-31
15289816
J Neurochem. 2003 Mar;84(5):1097-109
12603833
Handb Exp Pharmacol. 2005;(168):117-45
16596773
Brain Res. 2004 May 8;1007(1-2):152-9
15064146
Clin Neuropharmacol. 2004 May-Jun;27(3):108-10
15190231
J Neurophysiol. 2001 Jan;85(1):72-83
11152707
Br J Pharmacol. 2004 Sep;143(2):227-34
15313883
Behav Pharmacol. 2002 Sep;13(5-6):451-63
12394421
J Neurosci. 2005 Mar 16;25(11):2874-84
15772347
J Neurosci. 2006 Aug 16;26(33):8531-6
16914679
Neuroscience. 1998 Mar;83(2):393-411
9460749
Synapse. 2004 Sep 1;53(3):159-67
15236348
Eur J Neurosci. 2003 Sep;18(6):1607-14
14511339
Prog Retin Eye Res. 2008 Sep;27(5):501-26
18725316
Nat Med. 2001 Oct;7(10):1151-4
11590440
Curr Opin Pharmacol. 2003 Feb;3(1):54-61
12550742
Handb Exp Pharmacol. 2005;(168):445-77
16596784
Eur J Pharmacol. 1999 Jul 2;376(1-2):23-6
10440085
Eur J Neurosci. 2002 Jun;15(12):2057-61
12099913
Eur J Neurosci. 2001 Jul;14(1):96-102
11488953
J Pharmacol Exp Ther. 2003 Jul;306(1):93-102
12660305
Pharmacol Biochem Behav. 2005 Jun;81(2):387-95
15935455
Neuroscience. 2002;109(3):451-60
11823058
Eur J Pharmacol. 2008 Jan 14;578(2-3):137-41
17931621
Lipids Health Dis. 2003 Aug 19;2:5
12969514
Ann Neurol. 2008 Dec;64 Suppl 2:S30-46
19127584
Trends Endocrinol Metab. 2007 Jan-Feb;18(1):27-37
17141520
Dialogues Clin Neurosci. 2007;9(4):413-30
18286801
Neuropsychopharmacology. 2007 Oct;32(10):2098-107
17299506
J Clin Psychiatry. 2003 Apr;64(4):459-65
12716250
J Neural Transm Suppl. 2009;(73):269-75
20411785
Neuropsychopharmacology. 2007 Feb;32(2):298-308
16760924
Eur J Pharmacol. 1999 Jan 22;365(2-3):133-42
9988095
Neurology. 2001 Dec 11;57(11):2108-11
11739835
Trends Neurosci. 2000 Jan;23(1):14-20
10631784
Brain Res. 1997 Jul 18;763(1):63-8
9272829
Life Sci. 1999;65(6-7):703-13
10462071
Expert Opin Pharmacother. 2003 Oct;4(10):1717-25
14521482
Synapse. 2002 Apr;44(1):23-35
11842443
Mov Disord. 2002 Jan;17(1):145-9
11835452
Neurosci Biobehav Rev. 2006;30(5):680-95
16574226
J Neurochem. 1999 Sep;73(3):1084-9
10461898
Brain Res. 2002 Nov 1;954(1):73-81
12393235
J Neurosci. 2007 Apr 4;27(14):3663-76
17409230
Mov Disord. 2004 Aug;19(8):990-1
15300675
Brain Res. 1991 May 3;547(2):267-74
1909204
J Pharmacol Exp Ther. 2009 Mar;328(3):822-8
19106171
Brain Res. 2000 Feb 28;857(1-2):56-65
10700552
Neurosci Biobehav Rev. 2006;30(2):215-38
16099045
Eur J Pharmacol. 2003 Nov 7;480(1-3):133-50
14623357
Behav Brain Res. 2009 Nov 5;203(2):304-7
19414037
Eur J Neurosci. 2003 Apr;17(8):1723-6
12752390
Ann Neurol. 2005 May;57(5):777-9
15852389
Curr Pharm Des. 2008;14(23):2317-25
18781982
Br J Pharmacol. 2009 Apr;156(7):1029-40
19220290
J Neurosci. 2008 Dec 24;28(52):14018-30
19109485
Physiol Rev. 2009 Jan;89(1):309-80
19126760
Neurobiol Aging. 2011 Apr;32(4):631-45
19419794
Annu Rev Physiol. 2009;71:283-306
19575681
Acta Psychiatr Scand. 1984 Feb;69(2):162-74
6142585
Biol Psychiatry. 2006 Mar 15;59(6):508-15
16199010
Arch Gen Psychiatry. 2008 Jul;65(7):772-84
18606950
Pharmacol Biochem Behav. 2005 Jun;81(2):300-18
15919107
CNS Neurol Disord Drug Targets. 2009 Dec;8(6):432-9
19839934
Pharmacol Ther. 2007 Apr;114(1):13-33
17349697
Prostaglandins Leukot Essent Fatty Acids. 2002 Feb-Mar;66(2-3):287-99
12052043
Pharmacopsychiatry. 2002 Mar;35(2):57-61
11951146
Eur J Pharmacol. 2001 Jan 26;412(2):R3-5
11165232
J Neurosci. 2003 Apr 15;23(8):3136-44
12716921
Prog Neurobiol. 2002 May;67(1):53-83
12126656
Trends Pharmacol Sci. 2001 Nov;22(11):565-72
11698100
Addict Biol. 2003 Jun;8(2):159-66
12850774
Eur J Neurosci. 1998 Sep;10(9):2825-30
9758152
Addict Biol. 2008 Jun;13(2):147-59
18482430
J Neurosci. 2007 Jan 24;27(4):791-5
17251418
Neuropharmacology. 2008 Feb;54(2):438-44
18054052
J Neurochem. 1993 Nov;61(5):1705-12
7901331
Neurochem Int. 2009 Jun;54(7):452-7
19428788
Nat Rev Drug Discov. 2008 May;7(5):438-55
18446159
J Pharmacol Exp Ther. 2005 Mar;312(3):875-83
15525797
Handb Exp Pharmacol. 2005;(168):479-507
16596785
Pharmacol Biochem Behav. 2005 Jun;81(2):263-84
15936806
Biochem Biophys Res Commun. 1999 Mar 16;256(2):377-80
10079192
Curr Opin Pharmacol. 2007 Dec;7(6):575-82
17904903
Eur J Pharmacol. 2007 May 7;562(1-2):82-91
17336288
J Neurochem. 2003 Feb;84(4):698-704
12562514
Am J Med Genet. 2001 Dec 8;105(8):749-52
11803524
Br J Pharmacol. 2008 May;154(2):369-83
18414385
Neuropsychopharmacology. 2004 Nov;29(11):2108-14
15354183
Neurobiol Dis. 2005 Jun-Jul;19(1-2):96-107
15837565
Prostaglandins Leukot Essent Fatty Acids. 2009 Oct;81(4):291-301
19570666
Physiol Rev. 2003 Jul;83(3):1017-66
12843414
Nature. 2007 Feb 8;445(7128):643-7
17287809
Neuropharmacology. 2002 Oct;43(5):857-67
12384171
Neuropharmacology. 2005 Jun;48(8):1105-16
15878779
CNS Neurol Disord Drug Targets. 2009 Dec;8(6):403-21
19839937
J Neurosci. 2001 Jan 1;21(1):109-16
11150326
Neuropharmacology. 2001 Jun;40(7):918-26
11378162
Exp Neurol. 2007 Nov;208(1):110-9
17900568
Neuropsychopharmacology. 2003 Jun;28(6):1160-7
12637958
Expert Rev Neurother. 2008 Jul;8(7):1037-48
18590475
Curr Opin Investig Drugs. 2009 Apr;10(4):305-10
19337950
Exp Brain Res. 2006 Jul;172(4):556-60
16710682
Int Rev Psychiatry. 2009 Apr;21(2):163-71
19367510
Neurotox Res. 2008 Oct;14(2-3):169-83
19073424
Psychopharmacology (Berl). 2001 Jun;156(1):79-85
11465637
Eur J Neurosci. 2002 Jun;15(11):1795-802
12081659
Am J Psychiatry. 2004 Jun;161(6):975-84
15169685
Neuropsychopharmacology. 2009 Feb;34(3):759-66
18754005
Neuropharmacology. 2009 Mar;56(3):676-83
19101577
Alcohol Clin Exp Res. 2001 Feb;25(2):277-82
11236843
Nat Neurosci. 1999 Apr;2(4):358-63
10204543
Mov Disord. 2008;23 Suppl 3:S534-47
18781680
Psychopharmacology (Berl). 2009 May;204(1):1-11
19099297
J Clin Psychopharmacol. 2008 Jun;28(3):317-24
18480689
Neurosci Lett. 2007 Jun 29;421(3):270-4
17574742
Curr Psychiatry Rep. 2005 Oct;7(5):344-51
16216152
J Neurosci. 2008 Oct 15;28(42):10496-508
18923026
Prog Neuropsychopharmacol Biol Psychiatry. 2004 Mar;28(2):355-60
14751433
Mol Neurobiol. 2007 Aug;36(1):102-12
17952655
J Neurosci. 2008 Dec 17;28(51):13985-94
19091987
Drug Alcohol Depend. 2002 Mar 1;66(1):77-84
11850139
Mol Psychiatry. 2003 May;8(5):466-7
12808424
Neuroscience. 1992;48(3):655-68
1376455
J Neurosci. 2004 Jan 7;24(1):53-62
14715937
J Neurosci. 1991 Feb;11(2):563-83
1992016
Neuroreport. 1999 Jun 3;10(8):1665-9
10501554
Neuropsychopharmacology. 2008 Jun;33(7):1667-79
17957223
Mol Psychiatry. 2002;7(5):515-8
12082570
Neuropharmacology. 2008 May;54(6):976-88
18371990
Brain. 2003 Jun;126(Pt 6):1252-70
12764049
Prostaglandins Leukot Essent Fatty Acids. 2002 Feb-Mar;66(2-3):301-7
12052044
Neuropharmacology. 2003 Apr;44(5):633-41
12668049
J Neural Transm (Vienna). 2007;114(8):1055-63
17370106
World Psychiatry. 2008;7(2):68-71
18560513
Neurotox Res. 2008 Oct;14(2-3):105-12
19073418
Neurology. 2004 Oct 12;63(7):1245-50
15477546
FASEB J. 2000 Jul;14(10):1432-8
10877836
Cell Mol Life Sci. 2006 Jul;63(14):1597-613
16699809
J Neurochem. 2010 Mar;112(6):1454-64
20050977
Int Rev Psychiatry. 2009 Apr;21(2):113-21
19367505
Handb Exp Pharmacol. 2005;(168):643-56
16596791
Int Rev Psychiatry. 2009 Apr;21(2):134-42
19367507
Mov Disord. 2004 Sep;19(9):1102-6
15372606
Eur J Pharmacol. 1996 Jan 11;295(2-3):163-8
8720580
Eur Arch Psychiatry Clin Neurosci. 2006 Oct;256(7):437-41
16788767
Neuropharmacology. 2008 Apr;54(5):815-23
18262573
Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8394-9
12060782
Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10269-73
9707636
Neuropharmacology. 2009;56 Suppl 1:226-34
18691604
Science. 1997 Jun 27;276(5321):2048-50
9197269
Int Rev Neurobiol. 2007;78:289-326
17349865
Eur J Neurosci. 2009 Jun;29(11):2177-86
19490092
Synapse. 2003 Jul;49(1):61-6
12710016
Expert Opin Ther Targets. 2006 Apr;10(2):203-10
16548770
J Neurochem. 2003 May;85(4):1018-25
12716433
Br J Pharmacol. 2005 Sep;146(2):167-9
16025140
Eur J Pharmacol. 2002 May 17;443(1-3):95-7
12044797
J Neurol Neurosurg Psychiatry. 1990 May;53(5):436
2351975
Schizophr Bull. 2008 Nov;34(6):1111-21
18723841
Neuroscience. 2001;103(1):9-15
11311783
Br J Pharmacol. 2001 Apr;132(8):1809-16
11309253
Neurosci Lett. 1998 May 1;246(3):169-72
9792619
Neurobiol Dis. 2005 Apr;18(3):591-601
15755685
Pharmacol Biochem Behav. 1981 Nov;15(5):779-83
6273940
Eur J Pharmacol. 2001 May 25;420(2-3):123-31
11408034
J Neurosci. 2005 Sep 14;25(37):8432-8
16162925
Psychiatry Res. 2006 Oct 30;147(2-3):249-56
16919917
Br J Pharmacol. 2007 Nov;152(5):671-5
17704826
Brain Res. 2007 Feb 23;1134(1):162-70
17196181
Neuroimage. 2009 Oct 15;48(1):186-90
19539765
J Neurosci. 2002 Aug 15;22(16):6900-7
12177188
Pharmacol Res. 2009 Aug;60(2):85-92
19428268
Mov Disord. 2007 Jul 30;22(10):1379-1389
17427940
Handb Exp Pharmacol. 2008;(184):435-77
18064422
Curr Opin Psychiatry. 2007 May;20(3):228-34
17415074
Trends Neurosci. 2006 Apr;29(4):225-32
16483675
Mol Cell Endocrinol. 2008 Apr 16;286(1-2 Suppl 1):S97-S107
18372102
Drug News Perspect. 2008 Apr;21(3):149-57
18560613